IP Library › Granted Patent US 10,308,970
Granted Patent B2
US 10,308,970 · App. 15/819,351 · Granted Jun 4, 2019

Methods for controlling fucosylation levels in proteins

Inventors: Pradip Nair (Bangalore, IN); Ramakrishnan Melarkode (Bangalore, IN); Rasika Venkataraman (Bangalore, IN); Laxmi Adhikary (Bangalore, IN); Ankur Bhatnagar (Bangalore, IN); Sunaina Prabhu (Sirsi, IN); Kriti Shukla (Ahmedabad, IN); Dinesh Baskar (Bangalore, IN); Saravanan Desan (Bangalore, IN); Harish Venkatraman Pai (Bangalore, IN); Jose Enrique Montero Casimiro (Havana, CU)
Assignee: BIOCON LIMITED
C12P21/005C07K16/00C07K16/2896A61K2039/505C07K2317/24C07K2317/41C07K2317/54C07K2317/72C07K2317/73C07K2317/732C07K2317/92C07K2319/30Y02A50/407
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,308,970
App. No.
15/819,351
Granted
Jun 4, 2019
Kind
B2
Abstract

The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions.

Claims (10)

1. A method for decreasing fucosylation and increasing Mannose 5 and GlcNAc 2 Man 3 GlcNAc 2 (G0) in the glycosylation pattern of an expressed antibody in an eukaryotic protein expression system, the method comprising:

providing a culturing medium;

introducing into the culturing medium the eukaryotic protein expression system, wherein the eukaryotic protein expression system comprises an expression cassette encoding the expressed antibody, wherein the expressed antibody is Itolizumab, wherein the eukaryotic protein expression system comprises mammalian cells, wherein the mammalian cells are CHO hamster cells;

adding manganese or manganese ions into the culture medium to form a manganese containing culture medium, wherein the manganese or manganese ions is in a concentration range of ≥0.075 mM-≤0.5 mM;

culturing the eukaryotic protein expression system in the manganese containing medium to obtain the expressed antibody; and

recovering the expressed antibody from the manganese containing medium, wherein the expressed antibody exhibits decreased fucose and increased levels of Mannose 5 and GlcNAc 2 Man 3 GlcNAc 2 (G0) in the glycosylation pattern compared to an expressed antibody cultured in a medium wherein no manganese or manganese ions were introduced into the culture medium.

2. The method according to claim 1 , wherein the antibody expressed in claim 1 demonstrates an increased ADCC activity compared to an antibody expressed in the absence of the manganese or manganese ions added to the culture medium.

3. The method according to claim 1 , wherein the antibody expressed in claim 1 binds to one or more cellular surface antigen involved in cell-mediated immune defense.

4. The method according to claim 1 , further comprising introducing amino acids to the culturing medium to maintain cell growth and expression of the antibody expressed in claim 1 .

5. The method according to claim 1 , wherein the manganese or manganese ions are in a concentration range of ≥0.1 mM-≤0.25 mM.

Priority Claims (2)
IN 3262/CHE/2013 · Jul 23, 2013 · national
IN 3265/CHE/2013 · Jul 23, 2013 · national
Continuity (2)
Continuation 14905350
Related Publication 20180087080A1 · Mar 29, 2018